Thioacetamide-Induced acute hepatic encephalopathy in rat: behavioral, biochemical and histological changes

ABSTRACT

As a serious neuropsychiatric disease, hepatic encephalopathy [HE] is a clinical condition with several types regarding chronicity and clinical diversity that can develop as a complication of both acute and chronic liver failure. This study evaluates changes in thioacetamide [TAA]-induced acute hepatic encephalopathy [AHE] in rat as an animal model. Both genders of C57BL6, BALB/C mice and Sprague Dawley rats; [10 animals in each group] were compared for induction of AHE to clarify which animal and gender were appropriate. The animals [10 male rats in each group] were categorized in 4 groups according to the dose of the TAA administered [200, 300 and 400 mg/kg of TAA at 24 h intervals for 4 days]. A control group was treated with solvent of TAA which was water [5 ml/kg/day]. The behavioral, biochemical markers of hepatic failure and histological aspects of thioacetamide [TAA] induced AHE and the correlation between the clinical severity and liver failure biomarkers were evaluated. Rat was shown to be an animal model of choice for AHE while the optimum dosage of TAA to induce AHE was 300 mg/kg/day at 24 h intervals for 4 days. The behavioral score was partially correlated with the rising of some biomarkers and pathological findings. Rat can be introduced as the animal of choice for AHE to study the pathophysiology, pharmacology and the survival rate of disease in liver transplant patients